DMAC - DiaMedica Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 542.74M
Enterprise Value 330.14M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)85.49
Price/Book (mrq)3.06
Enterprise Value/Revenue 360.28
Enterprise Value/EBITDA 6-3.55

Trading Information

Stock Price History

Beta (3Y Monthly) 2.34
52-Week Change 3-60.02%
S&P500 52-Week Change 36.04%
52 Week High 310.4600
52 Week Low 32.4600
50-Day Moving Average 33.9727
200-Day Moving Average 33.6204

Share Statistics

Avg Vol (3 month) 3116.6k
Avg Vol (10 day) 382.4k
Shares Outstanding 511.96M
Float 9.07M
% Held by Insiders 18.37%
% Held by Institutions 113.72%
Shares Short (Jun 28, 2019) 469.52k
Short Ratio (Jun 28, 2019) 40.31
Short % of Float (Jun 28, 2019) 40.65%
Short % of Shares Outstanding (Jun 28, 2019) 40.58%
Shares Short (prior month May 31, 2019) 415.92k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 220/1
Last Split Date 3Nov 15, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,703.20%

Management Effectiveness

Return on Assets (ttm)-45.50%
Return on Equity (ttm)-89.45%

Income Statement

Revenue (ttm)500k
Revenue Per Share (ttm)0.05
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)500k
EBITDA -8.5M
Net Income Avi to Common (ttm)-8.34M
Diluted EPS (ttm)-0.9160
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)13.72M
Total Cash Per Share (mrq)1.15
Total Debt (mrq)217k
Total Debt/Equity (mrq)1.56
Current Ratio (mrq)10.49
Book Value Per Share (mrq)1.16

Cash Flow Statement

Operating Cash Flow (ttm)-7.89M
Levered Free Cash Flow (ttm)-4.84M